Analysts' Upgrades, Downgrades: Goldman - TheStreet

Change in Ratings



upgraded at Goldman Sachs to Buy from Neutral based on potential market share gains in the wake of


(AIG) - Get Report

problems. Note strong balance sheet and credit rating, as well as valuation. Price target raised to $67 from $61.


(ASH) - Get Report

upgraded at JPMorgan from Neutral to Overweight. Stock has pulled back 24% since the beginning of the month and looks attractive on an earnings basis.


(CL) - Get Report

downgraded at Goldman Sachs to Neutral from Buy based on stronger U.S. dollar and pullback in commodity prices. See strong fundamentals but believe multinational companies no longer have advantage vs. commoditized names. Price target raised to $61 from $54.

Goldman Sachs

(GS) - Get Report

upgraded at Wachovia from Market Perform to Outperform. Company remains in a position of power within the industry, and the stock should trade back up toward 1.5 times book value.


(KMB) - Get Report

upgraded at Goldman Sachs to Buy from Neutral based on upside earnings potential due to lower oil prices, ongoing sales momentum and attractive valuation. Price target raised to $71 from $58.



upgraded at BB&T to Buy. Valuation call, based on a $132 target. Company has the best fundamentals in the industry, and the stock is down 26% over the past three months.

Penske Automotive

(PAG) - Get Report

downgraded at Wachovia to Market Perform. Slower sales in the U.K. and continued luxury softness in the U.S. will weigh on earnings.


(TRV) - Get Report

upgraded at Goldman to Buy from Neutral. Believe company is well-positioned to gain market share following credit shakeout. Note strong balance sheet, strong credit rating and favorable valuation. Price target raised to $57 from $49.


(TUP) - Get Report

downgraded at JP Morgan from Overweight to Neutral. Slower international sales could cut into overall growth. Prefer

Newell Rubbermaid

(NWL) - Get Report

at current levels.

Stock Comments/EPS Changes


(GILD) - Get Report

price target trimmed at Goldman to $58 from $59 following negative complete response letter from FDA on aztreonam lysine. Based on response, 2008 and 2009 sales expectations reduced by $20 million and $110 million that were estimated for the drug. Note that company will continue working with the FDA to satisfy agency's needs. Maintained Buy rating.

This article was written by a staff member of